Celgene Acquires Avila Therapeutics for $350,000,000
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2499cad8-337f-4063-b44d-f647474f9561&Preview=1 -
Date
1/27/2012 -
Company Name
Avila Therapeutics -
Mailing Address
45 Wiggins Avenue Bedford, MA 01730 -
Company Description
Avila Therapeutics, Inc., is a venture-backed company focused on the discovery and development of novel small molecule therapeutics to address significant unmet clinical needs with an initial focus on cancer and viral diseases. -
Website
http://www.avilatx.com -
Transaction Type
M&A -
Transaction Amount
$350,000,000 -
Transaction Round
-
Proceeds Purposes
-
M&A Terms
Under the terms of the merger agreement, Celgene will acquire Avila Therapeutics, Inc. for $350 million in cash, plus up to $195 million for milestones contingent upon the development and regulatory approval of AVL-292, as well as up to $380 million in potential milestone payments contingent upon the development and approval of candidates generated from the Avilomics platform.
